• Skip to primary navigation
  • Skip to main content
  • Skip to footer

HepVu

HepVu

An estimated 3.5 million people in the U.S. are living with chronic Hepatitis C infection.

  • INTERACTIVE MAP
  • Location Profiles
  • Find Services
  • News & Updates
  • Events
  • Tools & Resources
Home Tools & Resources Deeper Look: Viral Hepatitis and Women in the U.S.

Deeper Look: Viral Hepatitis and Women in the U.S.

Viral hepatitis is a significant but often overlooked public health issue that can affect women across the United States. Hepatitis B and C, in particular, can lead to long-term liver damage, including cirrhosis and liver cancer, if left undiagnosed or untreated. Women face unique challenges related to hepatitis, such as increased risk during pregnancy, potential transmission to newborns, and barriers to testing and care in reproductive healthcare settings.

In the U.S., thousands of women live with chronic hepatitis—many without knowing it. Raising awareness, promoting screening, and improving access to treatment are key steps in protecting women’s health and preventing the spread of infection.

The most recent data highlight how viral hepatitis impacts women across the United States:

  • Hepatitis A: Outbreaks have impacted both men and women, and data indicate that adult women who are unvaccinated remain vulnerable, particularly those with underlying health conditions or who are experiencing homelessness.
  • Hepatitis B: Screening during pregnancy remains critical to preventing mother-to-child transmission. CDC recommends HBV screening for all pregnant women during each pregnancy, preferably in the first trimester.
  • Hepatitis C: While men historically have had higher overall rates of hepatitis C, new infections among women have increased—particularly among young women of reproductive age. Hepatitis C screening is recommended for all pregnant women as maternal hepatitis C infection is associated with pregnancy complications (including preterm birth, cesarean delivery, being small for gestational weight, and NICU admission) and the virus can be transmitted from mother to infant.

Social Determinants of Health and Barriers for Women at Risk for Viral Hepatitis

Viral hepatitis affects women of all backgrounds and can be particularly challenging for women in underserved communities. Factors such as limited access to healthcare, language and cultural barriers, lack of insurance, and stigma related to both viral hepatitis and risk behaviors can delay diagnosis and treatment. In rural areas and some urban settings, limited availability of testing and treatment services make early intervention more difficult. These factors underscore the need for equitable healthcare policies and outreach programs that can reach women most at risk.

Women engaged in sex work and women who inject drugs are at increased risk for viral hepatitis due to a range of factors, including limited access to preventive healthcare, exposure to unsafe sexual practices and sharing of syringes and other injection equipment.  Structural barriers such as criminalization, discrimination, and stigma may further limit their ability to seek care or protect themselves. These women may fear legal repercussions if they are diagnosed or seek treatment, which in turn prevents them from accessing life-saving healthcare services. Addressing the needs of these populations through inclusive, nonjudgmental, and accessible services is crucial in broader efforts promoting viral hepatitis elimination.

Additionally, gender-based discrimination and cultural norms may place women in subordinate roles, limiting their autonomy and access to healthcare, particularly in settings where women face economic, social, or gender-based barriers. These environments may make it more difficult to seek healthcare without permission or support from spouses, partners, and other male relatives. Moreover, stigma often intersects with gender-based discrimination and can make women fear judgement for behaviors considered socially unacceptable, such as drug use or sex with multiple partners. . This fear of judgment and social ostracism can lead women to delay seeking diagnosis and treatment. Competing priorities, such as caregiving responsibilities for children or elderly family members, can also limit women’s ability to prioritize their own health needs. In societies where women are expected to put the needs of their families first, the time and financial resources necessary for healthcare may be inaccessible or deprioritized. These compounded obstacles contribute to a cycle of neglect for women’s health needs, especially for conditions that are often “silent,” like chronic viral hepatitis.

Women living with HIV are also at increased risk for viral hepatitis, and co-infection with HIV and hepatitis is not uncommon due to shared modes of transmission. HIV can accelerate the progression of Hepatitis B and C infections, leading to more rapid liver damage and increased morbidity.  Integrating HIV and viral hepatitis screening and treatment services is critical to improving health outcomes among women living with both conditions.

Furthermore, the involvement of women and girls in research related to hepatitis prevention, diagnosis and treatment remains limited, leading to a gap in understanding the unique needs and experiences of women. Without a clear focus on gender-specific factors in medical research, treatment protocols may fail to address the challenges women face in managing hepatitis, leading to sub-optimal health outcomes for women.

All these factors together create a complex web of challenges that disproportionately affect women, ultimately resulting in delayed diagnosis, inadequate treatment, and poor long-term health outcomes. Addressing these health determinants requires multifaceted interventions that address the intersections of healthcare access, stigma, gender-based discrimination, and criminalization while ensuring that women’s issues and needs are adequately addressed in viral hepatitis research and healthcare policies.

Share our Infographics

Download
Share Facebook Twitter Pinterest LinkedIn
Download
Share Facebook Twitter Pinterest LinkedIn
Download
Share Facebook Twitter Pinterest LinkedIn
Download
Share Facebook Twitter Pinterest LinkedIn
Download
Share Facebook Twitter Pinterest LinkedIn
Download
Share Facebook Twitter Pinterest LinkedIn
Download
Share Facebook Twitter Pinterest LinkedIn
Download
Share Facebook Twitter Pinterest LinkedIn
Download
Share Facebook Twitter Pinterest LinkedIn

Preventing Viral Hepatitis

To prevent Hepatitis B and C, women can take several targeted steps that address the primary modes of transmission and promote personal and community-based prevention strategies. Here’s an expanded look at specific prevention methods for these two viral infections:

  1. Sex Education and Safer Sex: Hepatitis B can be transmitted through condomless sex. Although, in theory, hepatitis C can also be transmitted through heterosexual intercourse, the risk is quite low, since infection with hepatitis C requires exposure to blood. Comprehensive sex education that teaches women about the risks of hepatitis transmission and emphasizes the importance of safe sex practices, such as using condoms, can reduce the risk of transmitting viruses like HIV and hepatitis B.  Condoms are especially important for women who may be at risk due to multiple sexual partners, sex work, or partners with known risks for hepatitis. In addition, understanding the potential for blood-borne transmission during sex—especially for hepatitis C—can also aid in reducing transmission risk.
  2. Vaccinations (Hepatitis B): Hepatitis B is preventable through vaccination, which is highly effective at protecting individuals from contracting the virus and helps to reduce the overall burden of viral hepatitis in high-risk populations. It is currently recommended that all adults between the ages of 19 and 59 years be vaccinated against hepatitis B. This is especially important for women at higher risk, such as healthcare workers, persons with multiple sexual partners, and those who come in close contact with family members who are infected with hepatitis B. The vaccine is typically given as a series of three doses, and it provides long-lasting immunity. Some vaccine formulations also provide protection against hepatitis A virus.  Unfortunately, there is currently no vaccine to protect against hepatitis C.
  3. SyringeServices Programs (Hepatitis C): Hepatitis C is most commonly transmitted through blood-to-blood contact, particularly from sharing syringes or other drug injection equipment. Women who inject drugs are at significant risk of hepatitis C transmission. Syringe services programs play a crucial role in reducing the transmission of hepatitis C by providing access to clean syringes, safe disposal of used syringes, harm-reduction education, and testing for hepatitis C and other bloodborne viruses like HIV and hepatitis B These programs can also offer an opportunity for women to access substance use treatment, counseling, and support services, which can further help reduce the risks of hepatitis C transmission.
  4. Testing: It is currently recommended that all persons be tested for both hepatitis B and hepatitis C at least once during their lifetimes. Persons who are at increased risk should be tested periodically as long as their risk persists (for example, continued drug injection). Both of these viruses can be present without symptoms in the early stages, and individuals may unknowingly transmit the virus to others.  Women who come from regions of the world with a much higher prevalence of hepatitis B (for example, Western Pacific region, Southeast Asia, and Africa) should also be considered at higher risk for infection.

In addition to personal preventive measures, community-based efforts to promote awareness, education, and access to healthcare are essential in empowering women to protect themselves from hepatitis B and C. By focusing on education, vaccination for hepatitis A and hepatitis B, harm reduction, and regular testing, women can reduce their risk of contracting these viral infections and improve their overall health outcomes.

Hepatitis B and C During Pregnancy

Hepatitis B and hepatitis C are liver infections that can significantly impact pregnancy outcomes and pose risks to both mothers and infants.

  • Gestational diabetes: Women with chronic hepatitis B or C are at a higher risk of developing gestational diabetes during pregnancy. This condition can lead to elevated blood sugar levels, which can complicate pregnancies and lead to birth complications such as preterm labor or need for cesarean section. The exact mechanism by which these infections contribute to gestational diabetes is still being studied, but liver dysfunction related to hepatitis B and C may interfere with insulin metabolism and hormone regulation.
  • Low birth weight and premature birth: Pregnant women with Hepatitis B or C may have an increased risk of delivering babies with low birth weight (less than 5.5 pounds) and premature birth (before 37 weeks of gestation). This is especially concerning because low birth weight can lead to a host of neonatal complications, such as respiratory issues, developmental delays, and a higher risk for infections. Hepatitis-related liver damage and the body’s immune response may also affect placental function, impairing nutrient transfer to infants, and increasing the likelihood of preterm labor.
  • Transmission to infants: Both hepatitis B and C can be transmitted from mother to child during pregnancy or childbirth. Hepatitis B is highly infectious, and transmission from mother to infant occurs in 40% of cases where the mother is positive for the virus—rates of hepatitis B transmission are even greater if the mother has high levels of circulating virus. Fortunately, vaccination of the newborn with hepatitis B vaccine and hepatitis B immune globulin immediately after birth can reduce this risk significantly. Hepatitis C transmission from mother to infant is less common (around 6-7% of cases), but it can still occur, primarily during childbirth when there is exposure to infected blood. Women who are co-infected with HIV are at higher risk of transmitting hepatitis C to infants. In some cases, women may be offered antiviral medications during pregnancy to reduce viral load and reduce the risk of transmission.

4 Ways to Use HepVu

Criminalization of Viral Hepatitis and Its Impact on Women

The criminalization of certain behaviors linked to viral hepatitis transmission (e.g., substance use, sex work) further exacerbates the challenges that women face when living with hepatitis B or C. In some places, laws exist that criminalize the transmission of infectious diseases, including viral hepatitis. These laws disproportionately affect women who may engage in high-risk behaviors such as injecting drugs or sex work, both of which are linked to higher rates of viral hepatitis transmission.

  • Legal consequences: Women who are arrested or incarcerated for drug use may face harsh penalties and restrictions on their access to healthcare, including viral hepatitis testing, vaccination, and treatment. In some cases, pregnant women with viral hepatitis may even fear prosecution if they unknowingly transmit the virus to their child. This criminalization can deter women from seeking prenatal care, testing, or treatment for hepatitis B or C out of fear of legal repercussions.
  • Impact on healthcare access: Criminalization leads to marginalization and may prevent women from accessing necessary healthcare services, including reproductive health care and maternal care. This can further exacerbate health inequities and limit access to preventive services that could reduce the transmission risk of viral hepatitis. Additionally, the legal fear around disclosure of viral hepatitis status can limit trust between women and healthcare providers, which ultimately impacts health outcomes.

Download Data

See the Data

Hepatitis C Prevalence

Hepatitis C Mortality

Additional Data

Archived Data

View Local Statistics

View local statistics for your state, and download high-impact data visualizations for your work

See the Data

Learn from Experts

November 19, 2020

Dr. Tatyana Kushner on Trends in Hepatitis B Among Women of Childbearing Age

Read More

February 6, 2018

Hepatitis C from the Bench to the Bedside and Beyond

Mark Sulkowski, MD is a Professor of Medicine at Johns Hopkins University. The advent of highly effective treatments for Hepatitis C represents remarkable scientific achievement marked by many important milestones including the recognition of non-A, non-B Hepatitis  (1975); identification of the virus (1989); development of in vitro systems to study the virus and potential antiviral

Read More

January 14, 2020

Vu Q&A: Dr. Heather Bradley on Hep C by Race, Sex, and Age

Heather Bradley, PhD, is an Assistant Professor of Epidemiology at Georgia State University and serves as HepVu Project Director. Q: Newly released data from your paper, “Hepatitis C virus prevalence in 50 U.S. states and D.C. by sex, birth cohort, and race: 2013–2016,” published in Hepatology Communications show the Hepatitis C epidemic’s continuing disproportionate burden

Read More

June 12, 2019

Vu Q&A: Michelle Rose on Perinatal Hepatitis C Transmission in Kentucky

Michelle Rose, MBA, is the Population Health Manager for Norton Healthcare in Kentucky. Q: How did you get involved in working in Hepatitis C, especially focusing on perinatal transmission? I spent close to 20 years working in humanitarian aid, primarily with infectious diseases and HIV in Sub-Saharan Africa. When I returned to the United States

Read More

April 9, 2020

Vu Q&A: Tennessee Department of Health & Perinatal Hep C

Read More

For More Information

Additional information about viral hepatitis elimination can be found at the following resources.

U.S. Centers for Disease Control and Prevention

Learn More

U.S. Department of Health and Human Services

Learn More

Office on Women's Health

Learn More

World Hepatitis Alliance

Learn More
Share Facebook Twitter LinkedIn Email

Sign up for HepVu updates.

Footer

AIDSVu HepVu

HepVu is presented by Emory University’s Rollins School of Public Health in partnership with Gilead Sciences, Inc.

  • About
  • FAQ
  • Data Methods
  • Datasets

Questions?
Info@HepVu.org

Media Inquiries
(202) 854-0480
Media@HepVu.org

Follow Us

  • Facebook
  • Twitter

© 2025 HepVu. All Rights Reserved.

  • Privacy Policy
  • Contact Us

Get HepVu in Your Inbox

Sign up to stay informed on new data, maps, expert Q&As, and infographics about Hepatitis C and opioids where you live.